Table 2 Lung Function
From: The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma
| Â | Day 1 Pre-dose | Day 7 Pre-dose | Day 7 1 hr post-dose |
|---|---|---|---|
GSK256066 (L) | 3.29 (2.88 to 3.69) | 3.36 (2.94 to 3.79) | 3.47 (3.04 to 3.90) |
Placebo (L) | 3.27 (2.85 to 3.69) | 3.26 (2.91 to 3.60) | 3.36 (2.99 to 3.73) |
Adjusted treatment difference GSK256066 vs placebo (L) | Â | 0.09 (-0.03 to 0.20) | 0.09 (-0.08 to 0.27) |